To evaluate the objective response rates CR and PR of FOLFIRI plus aflibercept as 1st line treatment in patients with mCRC
Data and Resources
- An open label non-randomized phase two trial in metastatic colorectal cancer mCRC with the combination of mFOLFIRI plus Aflibercept as first treatment: MINOAS trialjson
To evaluate the objective response rates CR and PR of FOLFIRI plus...
|Release Date|| |
|Public Access Level|| |